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Abstract
Introduction: We aimed to quantify and identify associated factors of linkage to HIV care following home-based HIV counselling
and testing (HBHCT) in the ongoing ANRS 12249 treatment-as-prevention (TasP) cluster-randomized trial in rural KwaZulu-Natal,
South Africa.
Methods: Individuals ]16 years were offered HBHCT; those who were identified HIV positive were referred to cluster-based
TasP clinics and offered antiretroviral treatment (ART) immediately (five clusters) or according to national guidelines (five
clusters). HIV care was also available in the local Department of Health (DoH) clinics. Linkage to HIV care was defined as TasP or
DoH clinic attendance within three months of referral among adults not in HIV care at referral. Associated factors were identified
using multivariable logistic regression adjusted for trial arm.
Results: Overall, 1323 HIV-positive adults (72.9% women) not in HIV care at referral were included, of whom 36.9% (n488)
linked to care B3 months of referral (similar by sex). In adjusted analyses (n1222), individuals who had never been in HIV
care before referral were significantly less likely to link to care than those who had previously been in care (B33% vs. 42%,
pB0.001). Linkage to care was lower in students (adjusted odds-ratio [aOR]0.47; 95% confidence interval [CI] 0.240.92)
than in employed adults, in adults who completed secondary school (aOR0.68; CI 0.490.96) or at least some secondary
school (aOR0.59; CI 0.410.84) versus 5 primary school, in those who lived at 1 to 2 km (aOR0.58; CI 0.440.78) or 25
km from the nearest TasP clinic (aOR0.57; CI 0.410.77) versus B1 km, and in those who were referred to clinic after ]2
contacts (aOR0.75; CI 0.580.97) versus those referred at the first contact. Linkage to care was higher in adults who reported
knowing an HIV-positive family member (aOR1.45; CI 1.121.86) versus not, and in those who said that they would take ART
as soon as possible if they were diagnosed HIV positive (aOR2.16; CI 1.134.10) versus not.
Conclusions: Fewer than 40% of HIV-positive adults not in care at referral were linked to HIV care within three months of
HBHCT in the TasP trial. Achieving universal test and treat coverage will require innovative interventions to support linkage to
HIV care.
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Introduction
Initiating antiretroviral treatment (ART) as early as possible
after acquiring HIV infection results in better health out-
comes, reducing HIV-related morbidity or mortality [1,2].
Further, decreasing viral load with ART significantly reduces
HIV transmission from the treated infected to the uninfected
sexual partner in HIV-discordant couples [35]. Results from
mathematical models suggest that universal and repeat HIV
testing followed by immediate ART initiation could substan-
tially decrease HIV incidence at population level [6]; this has
been supported by subsequent results from an observational
cohort study in rural KwaZulu-Natal, South Africa [7]. The
World Health Organization (WHO) recently updated its HIV
treatment and prevention guidelines, recommending univer-
sal test and treat with ART to be initiated in anyone living
with HIV, regardless of clinical or immunological stage [8].
This was translated into the programmatic UNAIDS HIV
‘‘909090’’ treatment targets, aiming for ‘‘90% of people
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living with HIV knowing their HIV status, 90% of those with
diagnosed HIV infection receiving ART and 90% of those
receiving ART having durable viral suppression’’ by 2020 [9].
South Africa carries one of the highest HIV burdens
worldwide, with an estimated 6.3 million people living with
HIV in 2013, and an HIV prevalence of 19.1% among 15- to
49-year-olds [10]. To achieve universal HIV testing in such a
high HIV prevalence setting, community-based HIV testing
services should be offered in addition to those offered in
health facilities [11]. Among them, Home-Based HIV Counsel-
ing and Testing (HBHCT) has been shown to be acceptable
and effective in increasing the number of people who know
their HIV status, especially in South Africa [1218], but there
are limited data on linkage to care following HBHCT [19].
Further, while it is crucial that all HIV-identified individuals
access HIV care and initiate ART as soon as possible, results
from studies in sub-Saharan Africa have previously shown
that many newly diagnosed HIV-positive people do not enter
HIV care immediately following HIV diagnosis consequently
delaying time to ART initiation [20,21].
The objectives of our analysis were to quantify the pro-
portion of adults never or not currently in care who linked to
HIV care within three months following an HIV diagnosis
through HBHCT and to investigate factors associated with
linkage to HIV care. The analysis was performed within the
context of a cluster-randomized trial of treatment as pre-
vention (TasP) conducted in rural and high HIV prevalence
area in KwaZulu-Natal province, South Africa.
Methods
Study setting
We used data from the ANRS 12249 TasP trial, an ongoing
cluster-randomized trial evaluating the effectiveness of im-
mediate ART on HIV incidence. The trial is implemented since
March 2012 in Hlabisa sub-district, northern KwaZulu-Natal,
South Africa, a largely rural area, with scattered homesteads,
an estimated HIV prevalence of 29% [22] and a decentralized
local HIV programme [23].
Trial procedures
The TasP trial protocol has been described previously [24,25].
HBHCT is offered every six months to eligible members of the
trial communities contacted during home visits. Household
members are informed about the trial objectives and pro-
cedures, and about ART eligibility criteria according to their
cluster of residence. All participants identified as HIV positive
receive a TasP referral card and are encouraged to access the
TasP trial clinic in their cluster, situated B45 minutes walking
distance from where they live.
In TasP trial clinics of the intervention clusters, ART initia-
tion is offered immediately to all HIV-positive adults regard-
less of their CD4 count or clinical staging. In control clusters,
ART initiation is offered according to South African guidelines
(March 2012April 2013: CD45350 cells/mL or WHO stage
IV; April 2013January 2015: CD45350 cells/mL or WHO
stage III/IV or pregnant women or tuberculosis co-infected).
TasP trial participants can also access HIV and ART care in the
Department of Health (DoH clinics).
The TasP trial started in 10 (25) clusters from March
2012 to July 2014, with a further 12 (26) clusters from July
2014, bringing the total number of clusters to 22 (211) at
full implementation. Each cluster is composed of an average
of about 1000 residents ]16 years. Data from the first
10 clusters were used for this analysis.
Study population
We included all residents aged ]16 years from both arms
of the trial who were (i) contacted by a fieldworker, (ii)
ascertained HIV positive (positive rapid HIV test result or self-
reported to be HIV positive), (iii) referred to a TasP clinic
between March 2012 and June 2014, and (iv) never been or
not in HIV care at the time of referral (i.e. no CD4 count or
viral load measurements in the DoH or TasP clinics in the
13 months before referral).
We excluded individuals with inconsistent dates (date of
first clinic visit, death or out-migration before the date of
first referral), as well as those with a period of observation
shorter than three months.We focused statistical analyses on
individuals without missing data for explanatory variables.
Outcome and explanatory variables
The outcome was linkage to HIV care following HIV diagnosis
within three months of first referral in individuals who had
never or not recently been in HIV care. Linkage to care was
defined as attending a TasP clinic (the variable used was date
of visit) or a DoH clinic (the variable used was date of last CD4
count or viral load measurement), after matching between
the TasP trial database and the ARTemis database. We
obtained ethics approval to match the TasP trial database
with the DoH HIV care and treatment database (ARTemis),
both developed and hosted at the Africa Centre [23].
Matching was based on South African ID number, first names,
last names, dates of birth and cell phone numbers. The period
of three months (i.e. 91 days) between first referral and
linkage to care was chosen in accordance with Fox et al. [26].
Matching between TasP and ARTemis databases was also
used to define the variable ‘‘HIV care status at referral’’ with
four categories: (i) newly diagnosed (positive rapid HIV test
through HBHCT, no self-report of HIV diagnosis and not in the
ARTemis database before referral); (ii) already diagnosed but
never accessed HIV care in the local HIV programme (self-
reported HIV positive through HBHCT, not in the ARTemis
database before referral); (iii) already accessed HIV care in the
local HIV programme but considered lost-to-follow-up (LTFU)
for 13 to 24 months (in ARTemis database before first referral
but no CD4 count or viral load measurements in the DoH or
TasP clinics in the 1324 months before referral); or (iv) LTFU
for more than 24 months.
Further explanatory socio-demographic and HIV-related
variables were based on questionnaires administered face
to face by trained interviewers during the repeat home-
based visits; we considered information from the home
visit before and closest to the date of first referral. We also
included trial calendar round (CR) of HBHCT at referral (CR1:
identification of HIV infection at the first home visit by HIV
fieldworkers; CR2/CR3: identification of HIV infection at the
second or the third home visit [individuals identified HIV
positive in CR2/CR3 could be those not tested for HIV during
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the first round (CR1) because they were not at home, they
refused to be tested, they seroconverted between rounds
or they had just become eligible because they turned
16 years old]).
Statistical analysis
Linkage to HIV care following HIV diagnosis was described
with KaplanMeier curves stratified by sex. The association
between sex and linkage to HIV care was estimated using a
log-rank test. Univariable and multivariable logistic regression
models were conducted to explore factors associated with
linkage to HIV care within three months of referral. For
ordinal variables, a test for trend was also conducted.
Multivariable analysis was adjusted for sex and trial arm,
and included variables associated with linkage to HIV care
with a p-value B0.20 in univariable analysis. The interactions
with sex and HIV care status at referral were tested, but no
interactions were found (Supplementary Table 1). Analyses
were carried out using STATA version 13.0 (StataCorp, College
Station, Texas).
Ethical approval
The trial was approved by the Biomedical Research Ethics
Committee (BREC) of the University of KwaZulu-Natal (BFC
104/11) and the Medicines Control Council of South Africa.
Our consent procedures include at home level, for each
survey round, verbal consent of the homestead’s owner and
of the head of household, as well as written individual
consent. For participants aged 16 or 17, we collect both the
consent of the participant and the consent of a parent or a
guardian.
Results
Of the 12,957 adults registered in the TasP trial, 9927
were ever contacted, of whom 8233 had their HIV status
ascertained. Of these, 2569 (31.2%) were identified HIV
positive and referred to a TasP clinic (Figure 1); and among
them, 29 adults were excluded because they had inconsistent
dates (n9) or their period of observation was B3 months
(n20). Of the remaining 2540 adults, 1323 were consid-
ered ‘‘never or not currently in care,’’ of whom 72.9%
(n965) were women.
At the time of referral, about 43% of included adults were
newly diagnosed and 26% had previously been diagnosed but
had never accessed care (Table 1); about 31% of adults had
already accessed HIV care in the local HIV programme
but were considered LTFU, half of them for 24 months.
About 60% of HIV-positive adults were identified as HIV
positive in the first round of fieldwork (Table 1, trial
characteristics).
Figure 1. Flowchart of the cohort, ANRS TasP trial, rural South Africa, 20122014.
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Table 1. Description of the study population at referral, ANRS TasP trial, rural South Africa, 20122014 (N1323)
Total
(N1323)
Women
(N965)
Men
(N358)
n (%) n (%) n (%)
HIV care status at referral
Never in care, newly diagnosed 567 (42.9) 381 (39.5) 186 (52.0)
Never in care, already diagnosed 346 (26.1) 247 (27.6) 79 (22.1)
LTFU 24 months 202 (15.3) 161 (16.7) 41 (11.4)
LTFU 1324 months 208 (15.7) 156 (16.2) 52 (14.5)
Socio-demographic characteristics
Age at referral (years)
1619 78 (5.9) 69 (7.1) 9 (2.5)
2029 464 (35.1) 356 (36.9) 108 (30.2)
3039 355 (26.8) 242 (25.1) 113 (31.6)
4049 189 (14.3) 127 (13.2) 62 (17.3)
5084 193 (14.6) 139 (14.4) 54 (15.1)
Missing 44 (3.3) 32 (3.3) 12 (3.3)
Education level
Primary or less 491 (37.1) 342 (35.4) 149 (41.6)
Some secondary 440 (33.3) 320 (33.2) 120 (33.5)
At least completed secondary 383 (28.9) 297 (30.8) 86 (24.0)
Missing 9 (0.7) 6 (0.6) 3 (0.9)
Occupational status
Employed 210 (15.9) 120 (12.4) 90 (25.1)
Student 109 (8.2) 89 (9.2) 20 (5.6)
Not student, not employed 985 (74.5) 741 (76.8) 244 (68.2)
Missing 19 (1.4) 15 (1.6) 4 (1.1)
Household wealth assetsa
Low 471 (35.6) 350 (36.3) 121 (33.8)
Middle 554 (41.9) 408 (42.3) 146 (40.8)
High 287 (21.7) 198 (20.5) 89 (24.9)
Missing 11 (0.8) 9 (0.9) 2 (0.5)
Characteristics relating to HIV knowledge and perception
Knowing HIV-positive family member
No 821 (62.5) 565 (59.2) 256 (71.5)
Yes 491 (37.1) 391 (40.5) 100 (27.9)
Missing 5 (0.4) 3 (0.3) 2 (0.6)
Would take ARV if diagnosed HIV positive
Agree 1216 (91.9) 876 (90.8) 340 (95.0)
Disagree 63 (4.8) 56 (5.8) 7 (2.0)
Don’t know 25 (1.9) 18 (1.9) 7 (2.0)
Missing 19 (1.4) 15 (1.5) 4 (1.0)
Think that people avoid HIV-positive individuals
Agree 470 (35.5) 356 (36.9) 114 (31.8)
Disagree 697 (52.7) 496 (51.4) 201 (56.2)
Don’t know 137 (10.4) 100 (10.4) 37 (10.3)
Missing 19 (1.4) 13 (1.3) 6 (1.7)
Think that people don’t blame HIV-positive individuals
Agree 707 (53.4) 515 (53.4) 192 (53.6)
Disagree 448 (33.9) 330 (34.2) 118 (33.0)
Don’t know 153 (11.6) 110 (11.4) 43 (12.0)
Missing 15 (1.1) 10 (1.0) 5 (1.4)
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The included population was relatively young (44% of
women and 32% of men were B30 years) and with a low
education level (35% of women and 41% of men did not go
to secondary school). A large proportion of the population
was neither employed nor studying (76% of women and
68% of men). Almost 41% of women and 28% of men
declared that they knew at least one other family member
who was HIV positive. About one-third of the included
population perceived stigma against HIV-positive individuals
(35% agreed that people of the community avoid HIV-
positive individuals and almost 34% disagreed that people of
the community don’t blame HIV-positive individuals). More
than 90% of men and women reported they would take ARVs
‘‘as soon as possible’’ if diagnosed HIV positive (Table 1).
Linkage to care proportion
Overall, 36.9% of included adults never or not currently in
HIV care at the time of referral were linked to care (in either
TasP or DoH clinic) within three months of HBHCT (Table 2).
Linkage to HIV care occurred mostly during the first month
after referral then increased slowly over time, with no
significant differences by sex (Figure 2).
Factors associated with linkage to HIV care within three
months of referral
For this analysis, we excluded individuals who died (n3) or
had out-migrated (n7) within three months of referral, as
well as those with missing values (n91). In total, 1222
individuals were thus included (Figure 1); included individuals
were more likely to have had previous contact with the local
HIV programme than those excluded before HIV identi-
fication within the TasP trial (20.8% vs. 31.9%, p0.002,
Supplementary Table 2).
HIV care status at referral was significantly associated with
linkage to HIV care (Table 3): 32.1% of individuals newly
diagnosed were linked to HIV care within three months of
referral, compared with 42.8% among those who had already
accessed HIV care previously but were LTFU for 24 months
at the time of referral linked to HIV care (adjusted odd ratio
[aOR]1.44, 95% confidence interval [CI] 1.002.06), and
56.9% among those LTFU for more than 13 to 24 months
(aOR0.2.52, CI1.773.61). No significant difference in
linkage to care percentages was observed between indivi-
duals who were newly diagnosed and those already diag-
nosed but having never been in care.
Linkage to care significantly decreased with education level
(p for trendB0.001) and was associated with occupational
status: 16.7% of students linked to HIV care compared to
42.5% of employed (aOR0.47, CI0.240.92). However,
linkage to care did not differ significantly between employed
individuals and those who were neither student nor employed.
Further, percentages of linkage to care were higher
in individuals who declared knowing at least another HIV-
positive familymember (42.1% vs. 35.0% among thosewho did
not know another HIV-positive family member, aOR1.45,
CI1.121.86), as well as in those who stated they would
agree taking ARVs ‘‘as soon as possible’’ if diagnosed HIV
positive (38.5% vs. 25.4% among those who didn’t agree,
aOR2.16, CI1.134.10).
Living closer to a TasP clinic was significantly associated
with increased linkage to care (p for trend B0.001). Finally,
adults who were ascertained HIV positive and referred to a
TasP clinic in the second or the third round of trial fieldwork
were less likely to be linked to HIV care (32.2% vs. 41.3%,
aOR0.75, CI0.580.97) (Table 3).
The percentages of linkage to care also increased sig-
nificantly with age (p trend B0.001), but this association lost
significance in the multivariable model. Household wealth
and stigma-related variables were not significantly associated
with linkage to care.
Table 1 (Continued )
Total
(N1323)
Women
(N965)
Men
(N358)
n (%) n (%) n (%)
Trial characteristics
Distance from home to the closest TasP clinic
B1 km 486 (36.7) 355 (36.8) 131 (36.6)
12 km 468 (35.4) 343 (35.5) 125 (34.9)
25 km 369 (27.9) 267 (27.7) 102 (28.5)
Calendar round at referral
CR1 793 (59.9) 590 (61.1) 203 (56.7)
CR2/CR3 530 (40.1) 375 (38.9) 155 (43.3)
Trial arm
Control 717 (54.2) 535 (55.4) 182 (50.8)
Intervention 606 (45.8) 430 (44.6) 176 (49.2)
LTFU, lost-to-follow-up; ARV, antiretroviral; CR, calendar round at referral.
aHousehold wealth assets had been defined in three categories (low, middle and high) in agreement with a principal component analysis
considering sources of energy, amenities and access to drinking water and toilet facilities in this populations [27].
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Discussion
In this rural area, fewer than 40% of individuals identified HIV
positive through HBHCT in the TasP trial, and who had never
or were not currently in HIV care, accessed an HIV clinic within
three months of referral. These results are in line with a
previous study in Kenya (42% linkage to care following HBHCT)
[28] but lower than seen in other studies in rural South Africa
(62%) [19], Uganda and South Africa (86%) [29]. However, it is
difficult to compare these studies as definitions of linkage
to care varied (especially regarding the time between HIV
diagnosis and linkage to care used in these studies) [19]. We
also observed that linkage to care, if it happened, was most
likely in the first month after referral; we hypothesize that this
pattern, also seen elsewhere [19], is suggestive of an
element of being ready to engage with HIV care and
treatment, and where this fits in terms of personal priorities.
Linkage to HIV care did not significantly differ according to
sex, a finding consistent with the Kenya study [28]. We
identified several other factors associated with linkage to HIV
care. The first was HIV care status at referral, which allows for
previous HIV diagnosis and care. Adults who had never been
in HIV care when identified as HIV positive during the TasP
trial were significantly less likely to link to HIV care than
those who had previously been in HIV care but had been
LTFU. This may suggest that the latter may have already come
to terms with their HIV diagnosis and may possibly already
have disclosed their HIV status to relatives and friends; it has
indeed previously been reported that HIV disclosure is
associated with access to HIV care following HBHCT in Kenya
[28]. Further, individuals who were previously in care may
have a better understanding of what is involved in HIV care
than those who never accessed HIV care and may thus be
Table 2. Linkage to HIV care within three months of referral, ANRS TasP trial, rural South Africa, 20122014 (N1323)
Total
(N1323)
Women
(N965)
Men
(N358)
n % n % n %
Linkage to clinics 488 36.9 349 36.2 139 38.8
Linkage to TasP clinic only 381 28.8 267 27.7 114 31.8
Linkage to DoH then to TasP clinics 39 3.0 28 2.9 11 3.1
Linkage to TasP then to DoH clinics 7 0.5 4 0.4 3 0.8
Linkage to DoH clinic only 61 4.6 50 5.2 11 3.1
Death 3 0.2 3 0.3 0 0.0
Out-migration 7 0.5 7 0.7 0 0.0
No linkage to clinics 825 62.4 606 62.8 219 61.2
DoH, Department of Health; TasP, treatment as prevention.
Figure 2. Cumulative incidence of linkage to TasP or DoH clinics within three months of referral, stratified by sex, ANRS TasP trial, rural
South Africa, 20122014 (N1323). DoH: Department of Health; TasP: treatment as prevention.
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Table 3. Factors associated with linkage to TasP or DoH clinics within three months of referral, ANRS TasP trial, rural South Africa,
20122014 (N1222  complete data)
Univariable analysis Multivariable analysisa
n % linkage OR 95%CI p* aOR 95%CI p*
HIV care status at referral
Never in care, newly diagnosed 529 32.1 1.00  B0.001 1.00  B0.001
Never in care, already diagnosed 304 31.6 0.97 0.721.32 0.97 0.711.34
LTFU 24 months 194 42.8 1.58 1.132.21 1.44 1.002.06
LTFU 1324 months 195 56.9 2.79 1.993.90 2.52 1.773.61
Socio-demographic characteristics
Sex
Men 336 39.6 1.00  0.39 1.00  0.47
Women 886 36.9 0.89 0.691.16 0.90 0.681.20
Age at referral (years)
1619 75 20.0 0.54 0.300.99 B0.001 0.77 0.401.48 0.40
2029 437 31.6 1.00  1.00 
3039 340 38.2 1.34 1.001.81 1.09 0.791.50
4049 185 44.3 1.72 1.212.46 1.16 0.771.74
5084 185 51.4 2.29 1.613.25 1.47 0.942.28
Education level
Primary or less 455 47.7 1.00  B0.001 1.00  0.01
Some secondary 407 33.7 0.56 0.420.73 0.68 0.490.96
At least completed secondary 360 29.4 0.46 0.340.61 0.59 0.410.84
Occupational status
Employed 200 42.5 1.00  B0.001 1.00  0.07
Student 102 16.7 0.27 0.150.49 0.47 0.240.92
Not student, not employed 920 38.9 0.86 0.631.18 0.94 0.671.31
Household wealth assets
Low 439 37.1 1.00  0.62
Middle 514 39.1 1.09 0.841.41
High 269 35.7 0.94 0.691.29
Characteristics relating to HIV knowledge and perception
Knowing HIV-positive family member
No 764 35.0 1.00  0.01 1.00  0.004
Yes 458 42.1 1.36 1.071.72 1.45 1.121.86
Would take ARV is diagnosed HIV positive
Agree 1141 38.5 1.83 1.013.34 0.06 2.16 1.134.10 0.03
Disagree 59 25.4 1.00  1.00 
Don’t know 22 27.3 1.10 0.363.33 1.18 0.373.76
Think that people avoid HIV-positive individuals
Agree 446 36.8 0.91 0.711.16 0.39
Disagree 652 39.1 1.00 
Don’t know 124 33.1 0.77 0.511.15
Think that people don’t blame HIV-positive individuals
Agree 661 38.1 1.03 0.801.32 0.87
Disagree 424 37.5 1.00 
Don’t know 137 35.8 0.93 0.621.39
Trial characteristics
Distance to the closest TasP clinic
01 km 447 45.0 1.00  B0.001 1.00  B0.001
12 km 433 33.7 0.62 0.470.82 0.58 0.440.78
25 km 342 33.0 0.60 0.450.81 0.57 0.410.77
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more inclined to re-engage with HIV care when provided with
a convenient alternative which is closer to them as in the
TasP trial. Among people who had never been in care, there
were no differences in linkage to care whether people were
newly diagnosed in the trial or not, which was also found in
Kenya [28]; these findings suggest that, beyond the need for
time required to process an HIV-positive status following
diagnosis [30,31], there are additional challenges for linkage
to care which should be explored further.
While stigma variables, as collected within the trial, were
not significantly associated with linkage to HIV care, people
who knew another family member to be HIV positive were
more likely to access HIV care than those who did not. This
could suggest that people with HIV history in the family may
have a better knowledge of HIV care and treatment and may
thus be more disposed to access HIV care themselves when
they are referred. They may also be more confident in
disclosing their HIV status, and trust they will receive family
support. This is especially important in a context where HIV
care is offered in dedicated services or clinics, separated from
general care, where patients are easily identified as HIV
positive, as it is the case in this TasP trial as well as in the
local HIV programme.
Linkage to care was also especially low in students (16.7%);
these individuals may be less economically and logistically
independent and may not consider HIV care a priority.
We also showed that people who were identified HIV
positive at the first home-based contact were significantly
more likely to link to HIV care than those identified HIV
positive only at second or third contact. People referred to
care for the first time only after several contacts may either
be recent HIV seroconverters, needing time to accept their
HIV status, or who refused HIV testing initially, and who, we
hypothesize, may be less inclined to access care once
diagnosed than those readily accepting an HIV test at the
first contact.
Linkage to HIV care was lower in people with higher
education levels. A possible suggestion for this may include
being able to afford HIV care outside of the trial if closer to
their place of employment (private sector, clinics outside of
the areas). Higher education level may also be associated
with being at work or engaged in other productive activity,
which could have hindered clinic attendance.
Linkage to HIV care also decreased significantly with dis-
tance to clinic. Although everyone lived within a 45-minute
walking distance to the trial clinic in their cluster, those
who were even closer to the clinic, and required less travel
time to access it, were more likely to link to care than
those who lived further away. We hypothesize that the
role of distance to clinic in linkage to care would be even
more important in settings where HIV clinics are not as
accessible as in the TasP trial area. Economic and logistic
barriers associated with distance to clinic would need further
investigation.
Finally, while it has not been considered in this study, an
association between perception of health status and linkage
to HIV care following HBHCT has been observed in other
settings in Kenya [28] and South Africa [19]. For a long
time in these countries, the public health message has been
to wait for the CD4 count to drop below a certain threshold
before being able to initiate ART. With the 2015 WHO
recommendation of ART initiation to all HIV-positive indivi-
duals regardless of clinical or immunological status, public
health messaging will need to change with specific education
and counselling at community and individual levels.
Given the number of individual-level factors associated
with a link to HIV care in our study, strategies of patient-
centred HIV care with specific social support should be
considered [32]. The engagement of health system navigators
who can call, visit people at home or in neutral places and, if
needed, escort them to clinic could also be proposed [33,34]
although this was not found to be successful in urban South
Africa [35,36]. For people who face difficulties in accessing a
clinic, home-based ART initiation with home-based care
could be implemented [37] although it remains important
to evaluate the impact of such an intervention on long-term
follow-up.
Our study has some methodological limitations. First, it
was nested in a large randomized trial with specific trial
clinics providing higher coverage of HIV care than would
ordinarily be available within a standard HIV programme.
Another limitation is that we do not know whether people
linked to care outside of both the TasP trial and the local HIV
programme, which could have led to an underestimation of
the proportion of linkage to HIV care. However, such an
underestimation is unlikely to be substantial as our definition
Table 3 (Continued )
Univariable analysis Multivariable analysisa
n % linkage OR 95%CI p* aOR 95%CI p*
Calendar round at referral
CR1 734 41.3 1.00  0.001 1.00  0.03
CR2/CR3 488 32.2 0.67 0.530.86 0.75 0.580.97
OR, odd ratio; 95%CI, 95% confidence interval; aOR, adjusted odd ratio; LTFU, lost-to-follow-up; ARV, antiretroviral; CR, calendar round at
referral; DoH, Department of Health; TasP, treatment as prevention.
*p, likelihood ratio test p-values.
aVariables included in the multivariable model: HIV care status, sex, age, education level, occupational status, knowing HIV-positive family
member, ARV if diagnosed HIV positive, distance to clinic, trial calendar round.
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of linkage to care considers a short time period (three
months) following referral during which people from this
relatively poor area would have found difficult to access HIV
care outside the area. Finally, we excluded about 10% of the
sample (who had missing data) in the analysis of factors
associated with linkage to HIV care; included individuals
may not be representative of the overall population as they
were more likely to have previously sought HIV care in the
local HIV programme before TasP trial implementation,
than excluded people. However, we did not observe other
statistically significant differences between included and
excluded participants, and the population size was sufficient
to statistically test factors associated with linkage to HIV care
in the trial.
Conclusions
A major strength is that the study has been conducted
prospectively within a large population. The results are
particularly relevant in the context of rapidly evolving HIV
care. Indeed, in the light of the recent findings from the
TEMPRANO and START trials [1,2] demonstrating the strong
clinical benefits of early ART at an individual level, inter-
national HIV guidelines have been expanded towards a
universal test and treat strategy [8]. The critical remaining
questions relate to how best to ensure operational imple-
mentation of such a strategy at a population level in order to
achieve the UNAIDS 909090 target [9]. Our results show
that an HBHCT intervention is useful not only to diagnose
HIV-positive individuals who do not know their HIV status,
but also to re-engage people previously in care but LTFU. We
also highlighted the challenges inherent in achieving the
second ‘‘90%’’ of the UNAIDS target: the number of people
linked to HIV care and initiating ART must be substantially
increased with combined interventions at the patient-level.
Such strategies will need to be fully evaluated in different
settings, including ours, at population level.
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